Hoth Therapeutics Inc., a biopharmaceutical company committed to developing innovative therapies for unmet medical needs, has collaborated with OnTargetx R&D Inc. to accelerate research for its cancer-fighting therapeutic, HT-KIT.

HT-KIT, Hoth’s preclinical therapeutic candidate, targets c-Kit, a receptor tyrosine kinase implicated in numerous cancers. This candidate holds the potential to revolutionize precision oncology therapies.

This immunohistochemistry study, conducted in partnership with Charles River Laboratories Montreal ULC, represents a key step in the preclinical development of HT-KIT and aligns with Hoth Therapeutics’ mission to accelerate groundbreaking therapies and address unmet medical needs in oncology.

The study focuses on:

• Development and optimization of staining methods for (c-Kit) markers, a critical target in HT-KIT therapeutic mechanism.
• Processing and qualitative evaluation of tissue samples by a board-certified pathologist to determine the presence of markers.
• Comprehensive reporting and insights to support the continued development of HT-KIT.

“This partnership is instrumental in our efforts to advance HT-KIT, a promising therapeutic aimed at targeting c-Kit in cancer treatments,” said Robb Knie, CEO at Hoth Therapeutics. “We are committed to driving innovative solutions that can transform patient care.”